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A B S T R A C T
Antiepileptic drugs (AEDs) and hormonal contraceptives may affect each other’s metabolism and clinical
efﬁcacy. Loss of seizure control and unplanned pregnancy may occur when these compounds are used
concomitantly. Although a large number of available preparations yield a plethora of possible drug
combinations, most of these drug interactions are predictable and, thus, avoidable.
Unfortunately, there is a substantial lack of data regarding the newer AEDs. Detailed understanding of
these issues is necessary for those who prescribe AEDs and/or hormonal contraception to women with
epilepsy, as well as for those who provide comprehensive care, education and counseling to them, in
order to reduce the unacceptably high number of unplanned pregnancies among women with epilepsy.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Patients using antiepileptic drugs (AEDs) face unique chal-
lenges regarding hormonal contraception. Combined oral contra-
ceptives (COCs) and AEDs can interact bi-directionally, resulting in
possible therapeutic failure of either treatment, which may lead to
unintended pregnancy and/or increased seizure activity. Con-
traceptive failure is a disaster for all women, but is particularly
critical for women with epilepsy (WWE) owing to the teratogenic
potential of the AEDs and other adverse effects on the developing
child [1,2]. Unfortunately, contraceptive failure in women using
AEDs is disturbingly common [3].
Treating WWE of fertile age includes systematic, ongoing and
accurate counseling to ﬁnd the optimal method of contraception.
The wide range of available AEDs and hormonal contraceptive
methods underlines the importance of being familiar with the
various pharmacokinetic properties of the drugs to achieve a better
understanding of potential drug–drug interactions. However,
several surveys suggest that health care professionals often have
limited knowledge on potential interactions between AEDs and* Corresponding author. Tel.: +45 35 45 80 97.
E-mail address: anne.sabers@regionh.dk (A. Sabers).
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who take COCs deny to have ever received information about this
speciﬁc issue [5–8]. It has also been shown that these women do
not always recall being given such information. This highlights the
need for regular, repeated counseling so they can make informed
choices [9].
When used properly, the oral contraceptive (OC) failure rate is
1% in healthy women, but 3–6% in WWE [10,11]. One study
demonstrated that less than 55% of WWE had planned their
pregnancy and OC failure was the cause of one in four unplanned
pregnancies [12].
Taking into account all of the above and the fact that AEDs are
not only used for the treatment of epilepsy but also for other, even
more frequent indications such as neuropathic pain, general
anxiety disorders, migraine and bipolar disorder, it is obvious that
physicians and other health care providers should have adequate
knowledge of possible interactions between hormonal contracep-
tion and AEDs.
2. Types of hormonal contraception
An increasing number of different hormonal contraceptives
have been introduced during the past decades (Table 1).served.
Table 1
Types of hormonal contraception.
Type Active ingredient Route of
administration
Combined oral contraceptive
(COC) (‘‘the pill’’)
Estrogen
+ progestin
Orally
Combined dermal patch Estrogen
+ progestin
Transdermally
Vaginal ring Estrogen
+ progestin
Intravaginally
Progestin-only pills (‘‘mini-pill’’
and ‘‘morning-after pill’’)
Progestin Orally
Progestin-only implants Progestin Subdermally
Progestin-only depot injections Progestin Intramuscularly
Progestin-only intrauterine device Progestin Intrauterine device
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Despite concerns regarding adverse cardiovascular and neo-
plastic effects, combined estrogen and progestin contraceptives
(COCs) are among the most widely used contraceptive agents
[13,14]. COCs (‘‘the pill’’) traditionally contain a combination of a
synthetic estrogen and a progestin. The composition in terms of
type and dose of the estrogen and progestin constituent has
changed considerably over time. While the oldest COCs contained
up to 150 mg estrogen (in the form of mestranol, a pro-drug of
ethinyl estradiol), subsequent preparations used gradually de-
creasing amounts of estrogen, in order to minimize the risk of
venous thrombosis, cardiovascular disease and other adverse
effects. The most recent agents contain only 20–35 mg ethinyl
estradiol (EE), the most commonly used estrogen used in COCs. The
dose of EE in these agents is too low to ensure suppression of
ovulation and serves mainly to provide proper cycle control,
whereas the progestin component is responsible for the con-
traceptive mechanisms which include inhibition of ovulation as
well as increased viscosity of the cervical mucus and reduced
endometrial suitability for ovum implantation [15]. Recently, a
new class of COC was introduced, containing estradiol valerate (a
prodrug of estradiol) and dienogest, a progestin, both dosed in the
2–3 mg range. Several beneﬁts have been suggested for this COC,
including reduction of strong menstrual bleeding and fewer
hormone-withdrawal symptoms [16].
Progestins are synthetic progestogens with a molecular
structure similar to endogenous progesterone, but their steroid
skeleton has been provided with different substituents to enhance
bioavailability, modify their molecular actions, and to prolong
their half-life [17]. The oldest progestin compound used in COCs,
norethynodrel, was chemically related to nortestosterone and was
associated with undesirable androgenic effects. Today, a large
number of progestins are used in COCs, including norethindrone,
levonorgestrel, norgestimate, norgestrel, desogestrel, and drospir-
enone. Still, some of them are chemically classiﬁed as nortestos-
terone derivatives. Progestins may show both weak androgenic
and antiandrogenic effects, depending on their structure and
receptor afﬁnity. Some progestins are prodrugs and show
progestogenic effects only after bioactivation [17].
An ordinary COC is usually taken once daily for 21 days followed
by a seven days pause (‘‘pill-free week’’) during which withdrawal
bleeding occurs, in order to mimic a menstrual cycle. Extended-
cycle regimens, e.g. 84 days with a 7-day gap, have been suggested
and seem to be safe and well-tolerated [18]. Even longer periods of
continuous intake (up to one year) have been reported in smaller
studies and case reports [19].
In addition to COCs, skin patches and vaginal rings which
contain an estrogen and a progestin are available. While the skin
patch releases the hormones into the systemic circulation andinduces suppression of ovulation, the vaginal ring acts predomi-
nantly locally.
2.2. Progestin-only methods
Progestin-only methods include the progestin-only pill (‘‘mini
pill’’, POP) as well as subcutaneous progestin implants, progestin-
releasing intrauterine devices (IUDs) and intramuscular depot
injections. The site of action of these methods varies and depends
not only on the mode of administration, but also on the dose. Low-
dose oral compounds act locally on the endometrium and by
decreasing tube-motility, while the higher-dosed oral preparations
as well as the subdermal and intramuscular methods act mainly by
suppression of ovulation [20].
2.3. Emergency contraception
Emergency contraceptives (‘‘morning-after pill’’) are progestin-
only tablets and must be taken as soon as possible after
unprotected sexual intercourse. The progestin used in the vast
majority of these agents is levonorgestrel, but in a higher dose as in
ordinary POPs.
2.4. Metabolism of hormonal contraceptives
The estrogen compound used in virtually all combined hormonal
contraceptive methods is 17-a-ethinyl estradiol (EE). The newly
introduced estradiol valerate is a prodrug and biotransformed to
the naturally occurring estradiol [21]. EE is extensively metabolized
and subject to signiﬁcant ﬁrst pass metabolism. More than 30% of
the dose undergoes gut wall metabolism, mainly by sulfotransfer-
ase (SULT) dependent conjugation [22]. Its further biotransforma-
tion is catalyzed by cytochrome P450 (CYP), uridine diphosphate
(UDP)-glucuronosyltransferase (UGT) 1A1 and SULT. All these
enzymes can serve as a site of metabolic drug–drug interactions.
Most of EE is hydroxylated to inactive metabolites, catalyzed pre-
dominantly by CYP3A4. Also CYP2C9, CYP2C8, CYP2C19, and
CYP3A5 are contributing but play a minor role [23]. The hydroxyl-
ated metabolites then undergo conjugation by UGT and SULT and
are subject to enterohepatic re-circulation.
Glucuronidation is inhibited by valproate, and induced by
phenobarbital, phenytoin and other enzyme inducing drugs. EE
itself may induce UGT enzymes, thereby affecting the metabolism
of drugs principally metabolized by this route such as lamotrigine
or paracetamol. Moreover, it has long been known, although not
widely acknowledged, that EE is a moderate inhibitor of various
CYP enzymes and can increase the serum concentrations of many
other drugs signiﬁcantly [24,25].
Similar to EE, the metabolism of progestins also involves CYP-
mediated hydroxylation, reduction, deacetylation, and subsequent
sulfatation (via SULT) and glucuronidation (via UGT) [17].
2.5. Speciﬁc drug–drug interactions
Previous studies and recommendations on the interaction
between hormonal contraceptives and AEDs have mainly focused
on the alteration of the estrogen component of the agents.
However, due to the ever-decreasing estrogen content in modern
COCs, it is now in fact the progestin component that provides
the major part of the contraceptive effect of modern COCs
[15,20]. Thus, the progestin component in modern COCs should
be in the spotlight of future studies on drug interactions with
modern hormonal contraceptives. Moreover, the example of
lamotrigine has brought to our minds that hormonal contra-
ceptives may interfere with the metabolism of AEDs and affect
their clinical efﬁcacy [26].
Table 2
Bi-directional drug interactions between hormonal contraceptives and antiepilep-
tic drugs.
AED may
be reduced
by COC
Ethinyl
estradiol
may be
reduced
by AED
Progestin
may be
reduced
by AED
References
Carbamazepine n.a. Yes Yes [24,28]
Eslicarbazepine n.a. Yes Yes [35]
Felbamate n.a. Yes Yes [31]
Gabapentin n.a. No No [38]
Lacosamide no No No [42]
Lamotrigine Yes No Yes [26,43,52]
Levetiracetam No No No [39,45]
Oxcarbazepine n.a. Yes Yes [34]
Perampanel n.a. No Yesa [36]
Phenobarbital n.a. Yes Yes [24,53]
Phenytoin n.a. Yes Yes [24,28,51]
Pregabalin n.a. n.a. n.a.
Retigabine/ezogabine No No No [48]
Ruﬁnamide No Yes Yes [54]
Stiripentol n.a. n.a. n.a.
Topiramate n.a. Yesa No [32,33]
Valproate Yes No No [37,44,45]
Zonisamide No No No [40,41]
COV: combined oral contraceptive; n.a.: no data available.
a dose dependent.
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enzyme inducers and can accelerate the metabolism of hormonal
contraceptives, thus increasing the risk of unplanned pregnancy,
see Table 2 [24,27,28]. These AEDs have also been shown to
increase the amount of sexual hormone binding globulin (SHBG) in
the blood [29,30]. With increased SHBG, the free, biologically
active proportion of endogenous and exogenous sexual steroid
hormones decreases.
Felbamate [31] and topiramate [32,33] are less potent inducers
and may alter plasma concentrations of hormonal contraceptives
to a lesser degree. Oxcarbazepine also has a lower potential to
enzyme induction, but unfortunately exerts a similar effect on
hormonal contraceptives as carbamazepine [34]. Eslicarbazepine
is the S-enantiomer of the active constituent of oxcarbazepine and
does also reduce the plasma concentrations of EE and progestins
[35]. As it is generally used with lower serum concentrations than
the racemic mother compound, the interaction effect might
theoretically be lower than for oxcarbazepine.
With some AEDs, the extent of enzyme induction may be dose-
dependent, but this is difﬁcult to quantify and subject to great
inter-individual variation. This can be exempliﬁed by topiramate
which in monotherapy at dosages less than 200 mg did not
signiﬁcantly affect the pharmacokinetics of combined COCs
containing 35 mg EE [32]. Thus, COCs containing 35 mg ethinyl
estradiol might remain sufﬁciently active in women receiving low
dose topiramate monotherapy. This is an important ﬁnding, as
many fertile women use low dose topiramate, particularly in
migraine prophylaxis. A selective, dose dependent induction of
progestin metabolism has been demonstrated for perampanel, an
effect thought to be clinically signiﬁcant at 12 mg [36]. It has not
yet been studied to what extent low dose POPs (‘‘mini-pills’’) may
be vulnerable at lower perampanel doses.
For all enzyme inducing AEDs it has generally been suggested
that women who are taking these AEDs use high-dose COCs, but
this advice is not evidence based. In fact, the ﬁrst reports on
contraceptive failure in WWE using enzyme inducing AEDs were
published in the 1970s, when COCs contained considerably higher
EE doses than today’s COCs. The additional use of barrier methods
of contraception is therefore also recommended [20].Available data, although sparse, suggest that neither valpro-
ate [37], gabapentin [38], levetiracetam [39], zonisamide [40,41],
nor lacosamide [42] affect the metabolism of COCs. These AEDs
may therefore be regarded as safe with respect to possible
contraceptive failure. Lamotrigine, however, may have a modest
decreasing effect on the plasma level of the levonorgestrel [43]
while the EE compound is not affected. When interpreting these
data it is important to consider that the women in these studies
were taking moderate-dose COCs that contained 35 mg EE
plus 150 mg levonorgestrel. It cannot be ruled out that the
contraceptive effect of low-dose COCs that contain less than
30 mg EE and only 75 mg progestin or low dose POPs may be
impaired by lamotrigine. Therefore, midcycle bleeding should
always alert the physician and the patient to the risk of
contraceptive failure.
While some AEDs may induce the metabolism of EE and
progestins, EE itself may affect the metabolism and serum
concentrations of other drugs through inhibition of CYP enzymes
and by induction of UGT enzymes. Thus, the metabolism of AEDs
may be affected by hormonal contraceptives. Indeed, both
lamotrigine and valproate serum concentrations are reduced
when EE is taken concomitantly [26,44,45], presumably due to
accelerated glucuronidation. The clinical relevance of the modest
effect on valproate is unclear. However, lamotrigine serum
concentrations may decrease by more than 50%, and therapeutic
failure in the form of increased seizure frequency/recurrence of
seizures has been reported [26].
The effect of COCs on lamotrigine both establishes and
vanishes within a few days after start and cessation of active EE
treatment [43,46], suggesting that induction and de-induction
of UGT occur much faster than seen with other metabolic
pathways, such as cytochrome P450. In women using COCs in a
common 28-day regimen, routine serum concentration mea-
surements of lamotrigine should thus be performed while they
are on day 7–21 of the new cycle, i.e. in pharmacokinetic
steady-state of active EE treatment, and not during the pill-free
week.
A study on the differential effects of EE and progestins
suggested that progestin-only methods do not alter the lamo-
trigine serum concentrations, a ﬁnding which is of practical
importance [47].
Licarbazine, the active monohydroxy metabolite of oxcarbaze-
pine, and its S-enantiomer, eslicarbazepine, are also metabolized
by UGT enzymes and may therefore be affected by EE, but this
effect is difﬁcult to study in a naturalistic setting, as these drugs are
usually not combined with contraceptive pills.
A potential effect of hormonal contraception has been studied
only for few other AEDs, namely levetiracetam, zonisamide,
lacosamide and retigabine/ezogabine. The available data suggest
that the metabolism of these AEDs is not affected [40–42,48,49].
To our knowledge, no speciﬁc drug interactions studies have
been carried out with respect to estradiol valerate and AEDs.
However, one study with postmenopausal WWE on hormone
replacement therapy with conjugated equine estrogens showed
that two subjects taking lamotrigine had a decrease in their
lamotrigine levels of 25–30% [50]. Studies on the interaction
potential of estradiol valerate are awaited.
Very few data about possible interactions between AEDs and
progestin-only contraceptive methods are available. Enzyme-
inducing AEDs increase the metabolism of progestins as well
as of estrogens, and POPs should not be regarded as effective.
It has also been shown that subdermal progestin implants do
not provide reliable contraception in WWE using enzyme-
inducing AEDs [51]. The authors are not aware of any speciﬁc
studies on possible interactions between AEDs and the
morning-after pill.
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Millions of fertile women use AEDs and hormonal contracep-
tion concomitantly. There are a large number of available
preparations and possible drug combinations, and the risk for
bi-directional drug–drug interactions is high. Most of these
interactions follow common patterns and mechanisms, which
makes them predictable and, thus, avoidable. Regrettably, failure
of either treatment, especially contraceptive failure resulting in
unplanned pregnancy, occurs in an unacceptably high proportion
of patients. Fertile women with epilepsy indeed need individually
tailored treatment with consideration of birth control. Detailed
understanding of these complex interactions is necessary for those
who prescribe AEDs and/or hormonal contraception to WWE, as
well as for those who provide comprehensive care, education and
counseling including contraceptive advice to these patients. Given
the magnitude of the problem and the general lack of data, health
authorities should demand adequate testing of possible interac-
tions with hormonal contraception before a new AED is granted
marketing authorization. Future research in this ﬁeld should focus
at least as much on progestins as on estrogens.
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